#160990

RSAR001 Soft tissue tumor cell line

Cat. #160990

RSAR001 Soft tissue tumor cell line

Cat. #: 160990

Unit size: 1/7 volume of T-175 flask/vial

Availability: 8-10 weeks

Organism: Human

Tissue: Soft tissue

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Medical-Industrial Translational Research Center

Institute: Fukushima Medical University

Primary Citation: Hakozaki et al. 2018. Anticancer res 38: 5035-5042. PMID: 30194147

Tool Details
Applications
Handling
References
Documentation

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: RSAR001 Soft tissue tumor cell line
  • Alternate name: RSAR001, RSAR1
  • Cancer: Sarcoma
  • Cancers detailed: Clear cell sarcoma;Soft tissue tumor
  • Research fields: Cancer
  • Organism: Human
  • Gender: Male
  • Tissue: Soft tissue
  • Donor: 43 years old male patient
  • Growth properties: Adherent
  • Description: Novel patient-derived cell lines (PDCs) have been constructed under the Fukushima Translational Research Project. Our comparative histological and comprehensive gene expression analyses have shown that the characteristics of PDCs were similar to their source tumors, even after long-term growth in culture conditions
  • Application: High-throughput screening, Xenograft model
  • Biosafety level: 1

Applications

  • Application: High-throughput screening, Xenograft model

Handling

  • Format: Frozen
  • Volume: 1 ml
  • Growth medium: RPMI1640 medium with 10% heat-inactivated FBS
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1/7 volume of T-175 flask/vial
  • Shipping conditions: Dry ice
  • Storage medium: CELLBANKER 2
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes
  • Characterisation tests: Pathogen and stelility test; Comprehensive gene expression analysis; Cancer panel sequencing; Whole exome sequencing; Anticancer drug susceptibility testing

References

  • Hakozaki et al. 2018. Anticancer res 38: 5035-5042. PMID: 30194147

Documentation